ADAP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.44%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $52,102.42

Adaptimmune Therapeutics Insider Trading History Chart

Adaptimmune Therapeutics Share Price & Price History

^$0.29

▲ +0.0108 (3.93%)

As of 05/2/2025 05:00 PM ET

Days: 30 | 90 | 365

Adaptimmune Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/17/2025	Elliot Norry	Insider	Sell	5,584	$0.58	$3,238.72	7,510
1/15/2025	Cintia Piccina	Insider	Sell	12,991	$0.57	$7,404.87	18,421
1/15/2025	Willaim C. Bertrand, Jr.	COO	Sell	9,803	$0.57	$5,587.71	13,756
1/13/2025	Elliot Norry	Insider	Sell	12,392	$0.59	$7,311.28	5,845
1/13/2025	Willaim C. Bertrand, Jr.	COO	Sell	9,739	$0.59	$5,746.01	5,845
6/18/2024	Cintia Piccina	Insider	Sell	24,531	$0.93	$22,813.83	38,293
1/16/2024	Adrian Rawcliffe	CEO	Sell	9,304	$0.79	$7,350.16	14,104
1/16/2024	Elliot Norry	Insider	Sell	2,287	$0.79	$1,806.73	3,363
1/16/2024	Willaim C. Bertrand, Jr.	COO	Sell	4,681	$0.79	$3,697.99	7,023
1/12/2024	Willaim C. Bertrand, Jr.	COO	Sell	5,220	$0.85	$4,437.00	7,874
1/11/2024	Adrian Rawcliffe	CEO	Sell	11,945	$0.84	$10,033.80	18,395
1/11/2024	Elliot Norry	Insider	Sell	4,009	$0.84	$3,367.56	6,104
9/1/2023	Adrian Rawcliffe	CEO	Sell	2,403	$0.78	$1,874.34	3,449
8/1/2023	John Lunger	Insider	Sell	3,096	$0.91	$2,817.36	4,718
7/10/2023	Garry E Menzel	Director	Sell	47,702	$0.91	$43,408.82	75,056
6/27/2023	Adrian Rawcliffe	CEO	Sell	2,333	$0.92	$2,146.36	3,519
1/31/2023	Cintia Piccina	Insider	Sell	11,890	$1.87	$22,234.30	19,535
1/17/2023	Adrian Rawcliffe	CEO	Sell	10,057	$1.86	$18,706.02	13,351
1/17/2023	John Lunger	Insider	Sell	4,440	$1.86	$8,258.40	7,264
1/12/2023	Adrian Rawcliffe	CEO	Sell	18,763	$1.71	$32,084.73	24,882
1/12/2023	Willaim C. Bertrand, Jr.	COO	Sell	4,973	$1.71	$8,503.83	8,121
1/11/2023	John Lunger	Insider	Sell	3,843	$1.75	$6,725.25	6,270
1/4/2023	Adrian Rawcliffe	CEO	Sell	5,073	$1.69	$8,573.37	6,631
1/4/2023	John Lunger	Insider	Sell	1,100	$1.69	$1,859.00	1,725
1/4/2023	Willaim C. Bertrand, Jr.	COO	Sell	3,584	$1.69	$6,056.96	5,781
9/1/2022	Adrian Rawcliffe	CEO	Sell	2,536	$1.97	$4,995.92	3,316
8/1/2022	John Lunger	Insider	Sell	2,983	$1.77	$5,279.91	4,829
7/5/2022	John Lunger	Insider	Sell	1,973	$1.68	$3,314.64	3,104
6/27/2022	Adrian Rawcliffe	CEO	Sell	2,562	$1.63	$4,176.06	3,290
5/20/2022	Gavin Wood	CFO	Buy	39,000	$0.29	$11,310.00	96,000

See Full Table

SEC Filings (Institutional Ownership Changes) for Adaptimmune Therapeutics (NASDAQ:ADAP)

31.37% of Adaptimmune Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Adaptimmune Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/10/2025	Key Client Fiduciary Advisors LLC	150,150	$30K	0.0%	-41.2%	0.058%
2/18/2025	Two Seas Capital LP	14,835,146	$7.99M	0.6%	N/A	5.798%
2/17/2025	Two Sigma Investments LP	76,347	$41K	0.0%	+33.5%	0.030%
2/17/2025	Two Sigma Advisers LP	70,735	$38K	0.0%	+492.0%	0.028%
2/17/2025	Bank of America Corp DE	2,862,330	$1.54M	0.0%	-38.5%	1.119%
2/14/2025	Jane Street Group LLC	326,937	$0.18M	0.0%	+87.7%	0.128%
2/14/2025	Two Seas Capital LP	14,835,146	$7.99M	0.7%	N/A	5.798%
2/14/2025	Long Focus Capital Management LLC	20,494,393	$11.04M	0.4%	+54.1%	8.009%
2/14/2025	Rock Springs Capital Management LP	2,483,468	$1.34M	0.1%	+2.4%	0.971%
2/13/2025	Renaissance Technologies LLC	2,526,524	$1.36M	0.0%	+52.5%	0.987%
2/13/2025	Invesco Ltd.	63,335	$34K	0.0%	+82.0%	0.025%
2/12/2025	JPMorgan Chase & Co.	916,941	$0.49M	0.0%	-12.3%	0.358%
2/11/2025	LPL Financial LLC	183,479	$99K	0.0%	+106.5%	0.072%
2/11/2025	Virtu Financial LLC	122,696	$66K	0.0%	+21.5%	0.048%
1/31/2025	Baillie Gifford & Co.	11,819,095	$6.37M	0.0%	-29.5%	4.619%
11/20/2024	Virtu Financial LLC	101,008	$96K	0.0%	+27.5%	0.039%
11/15/2024	Jane Street Group LLC	174,157	$0.17M	0.0%	+130.4%	0.068%
11/15/2024	Matrix Capital Management Company LP	37,681,515	$35.81M	1.7%	-3.3%	14.734%
11/14/2024	PFM Health Sciences LP	10,000,787	$9.51M	0.5%	-4.9%	3.911%
11/13/2024	FMR LLC	1,740,900	$1.66M	0.0%	+3.0%	0.681%
11/5/2024	Baillie Gifford & Co.	16,775,860	$15.94M	0.0%	+10.7%	6.560%
11/5/2024	GSA Capital Partners LLP	99,662	$95K	0.0%	N/A	0.039%
10/29/2024	Fullcircle Wealth LLC	35,000	$33K	0.0%	N/A	0.014%
10/16/2024	Vontobel Holding Ltd.	43,000	$41K	0.0%	+230.8%	0.017%
8/15/2024	Long Focus Capital Management LLC	12,346,417	$12.04M	0.5%	+15.6%	5.002%
8/14/2024	Marshall Wace LLP	144,880	$0.14M	0.0%	-43.0%	0.059%
8/9/2024	Renaissance Technologies LLC	1,786,341	$1.74M	0.0%	+28.3%	0.724%
7/25/2024	Baillie Gifford & Co.	15,149,203	$14.77M	0.0%	-4.6%	6.138%
5/15/2024	Baker BROS. Advisors LP	10,787,022	$17.04M	0.2%	-1.7%	4.370%
5/14/2024	Boulder Hill Capital Management LP	90,800	$0.14M	0.1%	N/A	0.037%
5/3/2024	GSA Capital Partners LLP	370,179	$0.59M	0.0%	-27.2%	0.150%
5/1/2024	Baillie Gifford & Co.	15,871,875	$25.08M	0.0%	-0.3%	6.431%
4/19/2024	JTC Employer Solutions Trustee Ltd	26,156	$41K	0.0%	N/A	0.003%
4/15/2024	Key Client Fiduciary Advisors LLC	268,655	$0.42M	0.2%	-20.2%	0.027%
4/15/2024	Columbia Advisory Partners LLC	15,585	$25K	0.0%	N/A	0.002%
3/5/2024	Twin Focus Capital Partners LLC	55,526	$44K	0.0%	N/A	0.006%
1/26/2024	Baillie Gifford & Co.	15,912,140	$12.62M	0.0%	-7.2%	1.600%
1/9/2024	Key Client Fiduciary Advisors LLC	336,620	$0.27M	0.2%	+6.4%	0.034%
1/8/2024	Harbor Capital Advisors Inc.	147,732	$0.12M	0.0%	+9.9%	0.015%
11/13/2023	Baillie Gifford & Co.	17,147,409	$13.38M	0.0%	-0.2%	1.725%
10/27/2023	Marquette Asset Management LLC	99,349	$77K	0.0%	N/A	0.010%
10/27/2023	Acuitas Investments LLC	479,764	$0.37M	0.2%	N/A	0.048%
10/20/2023	Harbor Capital Advisors Inc.	134,415	$0.11M	0.0%	+19.5%	0.014%
9/21/2023	Barclays PLC	50,061	$46K	0.0%	N/A	0.005%
9/7/2023	MPM Asset Management LLC	6,287,101	$5.82M	2.9%	N/A	0.632%
8/15/2023	Black Maple Capital Management LP	69,839	$65K	0.0%	N/A	0.007%
8/14/2023	X Square Capital LLC	26,771	$25K	0.0%	N/A	0.003%
8/14/2023	CSS LLC IL	90,702	$84K	0.0%	N/A	0.009%
8/11/2023	Artal Group S.A.	1,133,775	$1.05M	0.0%	N/A	0.114%
8/7/2023	Acadian Asset Management LLC	358,010	$0.33M	0.0%	+15.1%	0.036%
8/3/2023	Oppenheimer & Co. Inc.	68,171	$63K	0.0%	N/A	0.007%
7/28/2023	Baillie Gifford & Co.	17,176,135	$15.89M	0.0%	+0.4%	1.728%
7/11/2023	Harbor Capital Advisors Inc.	112,516	$0.10M	0.0%	N/A	0.073%
5/17/2023	Long Focus Capital Management LLC	5,435,439	$5.93M	0.3%	+2.9%	3.514%
5/12/2023	Long Focus Capital Management LLC	2,772,791	$3.02M	0.3%	-47.5%	1.793%
5/10/2023	Simplify Asset Management Inc.	150,000	$0.16M	0.0%	N/A	0.097%
5/3/2023	Baillie Gifford & Co.	17,112,002	$18.65M	0.0%	-0.3%	11.064%
5/1/2023	Virtu Financial LLC	88,234	$96K	0.0%	+193.1%	0.057%
4/25/2023	Key Client Fiduciary Advisors LLC	321,155	$0.35M	0.2%	+8.2%	0.208%
2/15/2023	Endurant Capital Management LP	1,733,236	$2.53M	1.0%	-3.1%	1.058%
2/14/2023	Susquehanna International Group LLP	28,126	$41K	0.0%	N/A	0.017%
2/9/2023	HBK Sorce Advisory LLC	70,000	$65K	0.0%	+100.0%	0.043%
1/17/2023	Key Client Fiduciary Advisors LLC	296,740	$0.43M	0.3%	-31.9%	0.181%
1/11/2023	Vigilare Wealth Management	28,800	$42K	0.0%	-21.7%	0.018%
11/15/2022	PFM Health Sciences LP	9,320,584	$10.02M	0.4%	+2.3%	5.689%
11/15/2022	Long Focus Capital Management LLC	4,789,490	$5.15M	0.5%	+2.4%	2.923%
11/15/2022	Endurant Capital Management LP	1,788,517	$1.92M	0.6%	-1.9%	1.092%
11/14/2022	HBK Sorce Advisory LLC	35,000	$32K	0.0%	N/A	0.021%
11/10/2022	ExodusPoint Capital Management LP	370,288	$0.40M	0.0%	+23.4%	0.227%
11/7/2022	Virtu Financial LLC	40,503	$44K	0.0%	+133.7%	0.025%
11/3/2022	Barclays PLC	340,068	$0.37M	0.0%	+34.6%	0.208%
10/27/2022	Baillie Gifford & Co.	14,664,936	$15.76M	0.0%	-4.3%	8.977%
10/12/2022	Key Client Fiduciary Advisors LLC	435,985	$0.47M	0.4%	+4.8%	0.267%
8/12/2022	Rafferty Asset Management LLC	217,123	$0.37M	0.0%	-59.5%	0.134%
8/11/2022	Alps Advisors Inc.	96,110	$0.16M	0.0%	N/A	0.059%
8/10/2022	Hunter Associates Investment Management LLC	28,500	$49K	0.0%	+42.5%	0.018%
8/8/2022	Baillie Gifford & Co.	15,321,346	$26.05M	0.0%	-0.4%	9.457%
7/11/2022	Vigilare Wealth Management	41,800	$71K	0.1%	N/A	0.026%
5/17/2022	Endurant Capital Management LP	2,160,890	$4.45M	1.2%	+140.7%	1.335%
5/16/2022	Eversept Partners LP	237,086	$0.49M	0.0%	-32.0%	0.151%
5/11/2022	GSA Capital Partners LLP	69,612	$0.14M	0.0%	-17.3%	0.044%
5/5/2022	Baillie Gifford & Co.	15,380,538	$31.68M	0.0%	+11.8%	9.805%
5/5/2022	Levy Wealth Management Group LLC	17,590	$36K	0.0%	N/A	0.011%
4/29/2022	Daiwa Securities Group Inc.	35,516	$73K	0.0%	+44.9%	0.023%
4/26/2022	Hunter Associates Investment Management LLC	20,000	$41K	0.0%	+81.8%	0.013%
4/21/2022	Inspire Investing LLC	31,928	$66K	0.0%	+107.4%	0.020%
4/21/2022	Inspire Advisors LLC	45,105	$93K	0.0%	+193.0%	0.029%
4/18/2022	Key Client Fiduciary Advisors LLC	420,447	$0.87M	0.7%	+58.0%	0.268%
2/14/2022	Long Focus Capital Management LLC	2,162,313	$8.11M	1.1%	N/A	1.384%
2/14/2022	Point72 Asset Management L.P.	565,208	$2.12M	0.0%	+640.8%	0.362%
2/14/2022	DAFNA Capital Management LLC	136,266	$0.51M	0.1%	N/A	0.087%
2/14/2022	Eversept Partners LP	348,716	$1.31M	0.1%	-21.6%	0.223%
2/14/2022	GSA Capital Partners LLP	84,129	$0.32M	0.0%	-82.6%	0.054%
2/11/2022	Syncona Portfolio Ltd	1,377,294	$5.17M	4.9%	N/A	0.882%
2/10/2022	Rafferty Asset Management LLC	606,763	$2.28M	0.0%	-18.1%	0.388%
2/8/2022	Bank of America Corp DE	538,111	$2.02M	0.0%	-26.5%	0.344%
2/8/2022	ProShare Advisors LLC	19,315	$72K	0.0%	-34.0%	0.012%
2/7/2022	Mitsubishi UFJ Kokusai Asset Management Co. Ltd.	69,140	$0.28M	0.0%	+13.6%	0.044%
2/3/2022	Daiwa Securities Group Inc.	24,515	$92K	0.0%	+59.4%	0.016%
2/3/2022	Inspire Investing LLC	15,393	$58K	0.0%	N/A	0.010%

Data available starting January 2016

See Full Table

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Today's Range

Now: $0.29

$0.28

$0.29

50 Day Range

MA: $0.33

$0.20

$0.59

52 Week Range

Now: $0.29

$0.20

$1.48

Volume

482,898 shs

Average Volume

1,756,444 shs

Market Capitalization

$73.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.84

Who are the company insiders with the largest holdings of Adaptimmune Therapeutics?: Adaptimmune Therapeutics' top insider shareholders include:
Garry E Menzel (Director)
Cintia Piccina (Insider)
Adrian Rawcliffe (CEO)
William C Bertrand Jr (COO)
Elliot Norry (Insider)
John Lunger (Insider)
Learn More about top insider investors at Adaptimmune Therapeutics.
Who are the major institutional investors of Adaptimmune Therapeutics?: Adaptimmune Therapeutics' top institutional shareholders include:
Key Client Fiduciary Advisors LLC — 0.06%
Learn More about top institutional investors of Adaptimmune Therapeutics stock.
Which institutional investors are selling Adaptimmune Therapeutics stock?: In the last quarter, ADAP stock was sold by these institutional investors:
Key Client Fiduciary Advisors LLC
During the last year, company insiders that have sold Adaptimmune Therapeutics company stock include:
Garry E Menzel (Director)
Cintia Piccina (Insider)
Adrian Rawcliffe (CEO)
Learn More investors selling Adaptimmune Therapeutics stock.